L J Esserman

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
    Laura J Esserman
    Breast Care Center, University of California at San Francisco, 1600 Divisadero St, 2nd Floor, Box 1710, San Francisco, CA 94115, USA
    J Clin Oncol 30:3242-9. 2012
  2. ncbi Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
    Laura J Esserman
    University of California San Francisco, 1600 Divisadero Street, Box 1710, San Francisco, CA 94115, USA
    Breast Cancer Res Treat 132:1049-62. 2012
  3. ncbi Analysis of molecular inversion probe performance for allele copy number determination
    Yuker Wang
    Affymetrix Inc, Shoreline Blvd, South San Francisco, CA 94080, USA
    Genome Biol 8:R246. 2007
  4. ncbi A comparison of RNA amplification techniques at sub-nanogram input concentration
    Julie E Lang
    Department of Surgery, UCSF Comprehensive Cancer Center, 1500 Divisadero Street, San Francisco, CA 94143, USA
    BMC Genomics 10:326. 2009
  5. ncbi Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
    Yunn Yi Chen
    Department of Surgery, University of California San Francisco, San Francisco, USA
    BMC Cancer 9:285. 2009
  6. ncbi Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis
    Jeffrey K Belkora
    Department of Surgery, University of California San Francisco, San Francisco, CA, USA
    BMC Cancer 9:127. 2009
  7. ncbi Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, King s College, London, UK
    BMC Cancer 8:339. 2008
  8. ncbi A role for biomarkers in the screening and diagnosis of breast cancer in younger women
    Laura J Esserman
    University of California, San Francisco, Department of Surgery, 1600 Divisadero Street, Box 1710, San Francisco, CA 94115, USA
    Expert Rev Mol Diagn 7:533-44. 2007
  9. ncbi Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
    Laura J Esserman
    Deptartment of Surgery, University of California San Francisco Medical Center, San Francisco, CA, USA
    Breast Cancer Res 7:R1153-8. 2005
  10. ncbi Applying the neoadjuvant paradigm to ductal carcinoma in situ
    Laura Esserman
    Department of Surgery, University of California San Francisco Medical Center, San Francisco, California 94115, USA
    Ann Surg Oncol 11:28S-36S. 2004

Research Grants

  1. Integrated Biomarkers to Characterize Breast Cancer Risk
    Laura Esserman; Fiscal Year: 2007

Detail Information

Publications59

  1. ncbi Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
    Laura J Esserman
    Breast Care Center, University of California at San Francisco, 1600 Divisadero St, 2nd Floor, Box 1710, San Francisco, CA 94115, USA
    J Clin Oncol 30:3242-9. 2012
    ....
  2. ncbi Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
    Laura J Esserman
    University of California San Francisco, 1600 Divisadero Street, Box 1710, San Francisco, CA 94115, USA
    Breast Cancer Res Treat 132:1049-62. 2012
    ..The ability of pCR to predict RFS is better by subset than it is for the whole group. Molecular markers improve prediction of RFS by identifying additional patients with excellent prognosis within the no pCR group...
  3. ncbi Analysis of molecular inversion probe performance for allele copy number determination
    Yuker Wang
    Affymetrix Inc, Shoreline Blvd, South San Francisco, CA 94080, USA
    Genome Biol 8:R246. 2007
    ....
  4. ncbi A comparison of RNA amplification techniques at sub-nanogram input concentration
    Julie E Lang
    Department of Surgery, UCSF Comprehensive Cancer Center, 1500 Divisadero Street, San Francisco, CA 94143, USA
    BMC Genomics 10:326. 2009
    ..Microarray data from each amplification method were validated against quantitative real-time PCR (QPCR) for 37 genes...
  5. ncbi Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
    Yunn Yi Chen
    Department of Surgery, University of California San Francisco, San Francisco, USA
    BMC Cancer 9:285. 2009
    ....
  6. ncbi Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis
    Jeffrey K Belkora
    Department of Surgery, University of California San Francisco, San Francisco, CA, USA
    BMC Cancer 9:127. 2009
    ..We hypothesized that Adjuvant! printouts would be associated with significant changes in the proportion of patients with accurate understanding of local therapy prognosis...
  7. ncbi Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, King s College, London, UK
    BMC Cancer 8:339. 2008
    ....
  8. ncbi A role for biomarkers in the screening and diagnosis of breast cancer in younger women
    Laura J Esserman
    University of California, San Francisco, Department of Surgery, 1600 Divisadero Street, Box 1710, San Francisco, CA 94115, USA
    Expert Rev Mol Diagn 7:533-44. 2007
    ..The most effective preventive strategies will be those where a marker predicts risk for the disease, as well as the benefit from preventive interventions...
  9. ncbi Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
    Laura J Esserman
    Deptartment of Surgery, University of California San Francisco Medical Center, San Francisco, CA, USA
    Breast Cancer Res 7:R1153-8. 2005
    ....
  10. ncbi Applying the neoadjuvant paradigm to ductal carcinoma in situ
    Laura Esserman
    Department of Surgery, University of California San Francisco Medical Center, San Francisco, California 94115, USA
    Ann Surg Oncol 11:28S-36S. 2004
    ....
  11. ncbi Integration of breast imaging into cancer management
    L J Esserman
    Department of Surgery, Carol Franc Buck Breast Care Center, University of California at San Francisco, 2356 Sutter Street, Sixth Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 2:572-81. 2000
    ..This article reviews the use of breast imaging for screening, diagnosis, and staging. Its focus is on the ways in which imaging techniques can most effectively be integrated into clinical management...
  12. ncbi Magnetic resonance imaging captures the biology of ductal carcinoma in situ
    Laura J Esserman
    Department of Surgery, University of California, San Francisco, USA
    J Clin Oncol 24:4603-10. 2006
    ..We investigated whether MRI features of DCIS reflect differences in biology and pathology...
  13. ncbi Rethinking screening for breast cancer and prostate cancer
    Laura Esserman
    Department of Surgery and Radiology, University of California, San Francisco, San Francisco, CA 94115, USA
    JAMA 302:1685-92. 2009
    ..To reduce morbidity and mortality from prostate cancer and breast cancer, new approaches for screening, early detection, and prevention for both diseases should be considered...
  14. ncbi MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer
    L Esserman
    Department of Surgery, University of California, San Francisco, USA
    Ann Surg Oncol 8:549-59. 2001
    ..Magnetic resonance imaging (MRI) demonstrates that patients with LABC have distinct tumor patterns. We investigated whether or not these patterns predict response to therapy...
  15. ncbi Improving the accuracy of mammography: volume and outcome relationships
    Laura Esserman
    Department of Surgery, University of California at San Francisco, 94143 1710, USA
    J Natl Cancer Inst 94:369-75. 2002
    ..We investigated whether high sensitivity can be achieved in the context of high specificity and whether the number of mammograms read per radiologist (reader volume) drives both sensitivity and specificity...
  16. ncbi Magnetic resonance imaging for primary breast cancer management: current role and new applications
    L Esserman
    Department of Surgery, University of California, Carol Franc Buck Breast Care Center, 1600 Divisadero Street, 2nd Floor, Box 1710, San Francisco 94115 3006, USA
    Endocr Relat Cancer 9:141-53. 2002
    ..In addition, we will address areas where MR is not yet capable of adding value or where MR may lead to unnecessary procedures...
  17. ncbi Impact of mammographic screening on the detection of good and poor prognosis breast cancers
    Laura J Esserman
    University California San Francisco, San Francisco, CA, USA
    Breast Cancer Res Treat 130:725-34. 2011
    ..In women over age 50, biologically low risk tumors are frequent and tools that classify risk may minimize overtreatment...
  18. ncbi Biologic markers determine both the risk and the timing of recurrence in breast cancer
    Laura J Esserman
    Department of Surgery and Radiology, University of California, San Francisco, CA 94115, USA
    Breast Cancer Res Treat 129:607-16. 2011
    ..Current signatures predict for outcome risk within 5 years of diagnosis. Predictors of late risk for HR positive disease are needed...
  19. ncbi Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity
    E Shelley Hwang
    Department of Surgery, University of California San Francisco, San Francisco, California 94115, USA
    Ann Surg Oncol 10:381-8. 2003
    ..We studied the performance of MRI in patients with known DCIS for assessment of residual disease, occult invasion, and multicentricity to determine the clinical role of MRI in this setting...
  20. ncbi Ductal carcinoma in situ in BRCA mutation carriers
    E Shelley Hwang
    University of California, San Francisco Cancer Risk Program and the Carol Franc Buck Breast Care Center, San Francisco CA, USA
    J Clin Oncol 25:642-7. 2007
    ....
  21. ncbi Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users
    Anjali S Kumar
    Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, USA
    Cancer Epidemiol Biomarkers Prev 17:1028-33. 2008
    ....
  22. ncbi Monitoring the implementation of Consultation Planning, Recording, and Summarizing in a breast care center
    Jeffrey K Belkora
    University of California, San Francisco, United States
    Patient Educ Couns 73:536-43. 2008
    ....
  23. ncbi New approaches to the imaging, diagnosis, and biopsy of breast lesions
    Laura J Esserman
    Department of Surgery and Radiology, University of California, San Francisco Cancer Center, 94115, USA
    Cancer J 8:S1-14. 2002
    ....
  24. ncbi Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma
    E Shelley Hwang
    Department of Surgery, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 100:2562-72. 2004
    ..The possible genomic relation between synchronous LCIS and ILC was analyzed using the technique of array-based comparative genomic hybridization (CGH)...
  25. ncbi Optimizing the total skin-sparing mastectomy
    Akushla Wijayanayagam
    Carol Franc Buck Breast Care Center, Department of Surgery, University of California, San Francisco, 1600 Divisidero St, Box 1710, San Francisco, CA 94115 1710, USA
    Arch Surg 143:38-45; discussion 45. 2008
    ..Dissection of subnipple tissue to spare the entire skin envelope of the breast (total skin-sparing mastectomy) is a feasible option in appropriately selected patients and yields an excellent final cosmetic outcome...
  26. ncbi Application of screening principles to the reconstructed breast
    Jennifer Zakhireh
    Department of Surgery, University of California, San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA 94115, USA
    J Clin Oncol 28:173-80. 2010
    ..In this review article, we will detail the reasons that should allow clinicians to forego routine surveillance imaging in the majority of women who undergo mastectomy and reconstruction...
  27. ncbi Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ
    Anjali S Kumar
    Department of Surgery, University of California San Francisco, San Francisco, CA, USA
    Am J Surg 192:520-4. 2006
    ..Benign proliferative processes often enhance on MRI and are difficult to differentiate from low-grade, ER+ DCIS lesions. False-positive MRI enhancement may reflect a spectrum of change within high-risk tissue...
  28. ncbi MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival
    Savannah C Partridge
    Department of Radiology, University of California, San Francisco, San Francisco, CA 94143, USA
    AJR Am J Roentgenol 184:1774-81. 2005
    ....
  29. ncbi Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation
    Julie E Lang
    Department of Surgery, University of California San Francisco, San Francisco, CA 94114, USA
    J Am Coll Surg 199:856-62. 2004
    ....
  30. ncbi Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial
    John A Olson
    Department of Surgery, Duke Comprehensive Cancer Center, Durham, NC, USA
    J Am Coll Surg 208:906-14; discussion 915-6. 2009
    ..A multicenter phase II clinical trial was conducted to investigate the value of this approach for US surgical practice...
  31. ncbi Type and duration of exogenous hormone use affects breast cancer histology
    Anjali S Kumar
    Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, 94602, USA
    Ann Surg Oncol 14:695-703. 2007
    ..We conducted this investigation to assess whether the type of hormone used (none, estrogen, progesterone, or combined) and duration of use influences subsequent breast cancer histology...
  32. ncbi Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment
    Catherine Park
    Department of Radiation Oncology, University of California, Mount Zion Medical Center, the UCSF Comprehensive Cancer Center, San Francisco, California, USA
    Breast J 11:29-33. 2005
    ..These factors may aid in the selection of patients who might benefit from further staging or treatment of the IMNs...
  33. ncbi Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
    Elisabeth R Garwood
    Department of Surgery, University of California, San Francisco, CA, USA
    Breast Cancer Res Treat 119:137-44. 2010
    ..Effects were only evident in high grade tumors. These results support further evaluation of statins as chemoprevention for ER-negative high grade breast cancers...
  34. ncbi Does timely assessment affect the anxiety associated with an abnormal mammogram result?
    J Haas
    Primary Care Research Center, Division of General Internal Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94143 0936, USA
    J Womens Health Gend Based Med 10:599-605. 2001
    ..Further work is needed to ascertain how to minimize the anxiety associated with the evaluation of an abnormal mammogram...
  35. ncbi Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer
    Julie E Lang
    Department of Surgery and UCSF Comprehensive Cancer Center, UCSF, San Francisco, CA 94143 1674, USA
    Breast J 15:242-6. 2009
    ..57), or overall survival (p = 0.70). Positive non-SLNs removed during SSL are not a significant risk factor for additional positive nodes on completion axillary nodal dissection (CALND) or for worse survival than positive SLNs...
  36. ncbi Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium
    Veronica Shim
    University of California at San Francisco Comprehensive Cancer Center, University of California, San Francisco, California 94115 1710, USA
    Cancer Res 63:2347-50. 2003
    ..Our observations demonstrate that COX-2 is up-regulated in the normal adjacent epithelium and supports the hypothesis that the surrounding epithelial tissue is part of the disease process in DCIS...
  37. ncbi Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy
    Savannah C Partridge
    Department of Radiology, University of California, San Francisco, Magnetic Resonance Science Center, 1 Irving St, Rm. AC-109, San Francisco, CA 94143-1290, USA
    AJR Am J Roentgenol 179:1193-9. 2002
    ..CONCLUSION: The high correlation between measurements of residual disease obtained on MR images and those obtained at pathology validates the sensitivity of MR imaging of the breast after chemotherapy...
  38. ncbi Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer
    Kelly M Adduci
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143 0808, USA
    Cancer 111:185-91. 2007
    ..For this study, the authors asked whether molecular analyses of DL specimens from women with cancer would identify abnormal cells, even if they appeared cytologically normal...
  39. ncbi Statins: health-promoting agents show promise for breast cancer prevention
    Anjali S Kumar
    Department of Surgery, University of California San Francisco, 94115, USA
    Clin Breast Cancer 6:455-9. 2005
  40. ncbi Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma
    Robert D Foster
    Division of Plastic and Reconstructive Surgery, University of California San Francisco, 350 Parnassus Avenue, San Francisco, CA 94143 0932, USA
    Ann Surg Oncol 9:462-6. 2002
    ....
  41. ncbi Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients
    Chen-Teng Wu
    Department of Surgery, University of California, San Francisco (UCSF) Medical Center at Mount Zion, 94143-1674, USA
    Breast J 9:86-90. 2003
    ..The possibility of failure to get the SLN should be explained to patients before surgery. Axillary lymph node dissection (ALND) should be done if selective SLN dissection is not successful...
  42. ncbi Breast cancer growth prevention by statins
    Michael J Campbell
    Department of Surgery, University of California San Francisco Mt Zion Medical Center, Room C342, 1600 Divisadero, San Francisco, CA 94115, USA
    Cancer Res 66:8707-14. 2006
    ..These findings provide supporting rationale for future statin trials in breast cancer patients...
  43. ncbi Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer?
    Liang Chih Liu
    Department of Surgery and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
    J Am Coll Surg 207:853-8. 2008
    ..We hypothesized that the node with the highest radioactivity would have the strongest probability of being a positive SLN, and we sought to determine the lowest radioactive count of a node harboring cancer...
  44. ncbi Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction
    Anne Warren Peled
    Division of Breast Surgery, Department of Surgery, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Arch Surg 145:880-5. 2010
    ..To determine the impact of chemotherapy and the timing of chemotherapy on postoperative outcomes after mastectomy and immediate breast reconstruction...
  45. ncbi Immune dysfunction and micrometastases in women with breast cancer
    Michael J Campbell
    Department of Surgery, University of California, San Francisco, CA 94115, USA
    Breast Cancer Res Treat 91:163-71. 2005
    ..These dysregulated T cell responses did not correlate with age, stage of disease, or nodal status. However, we did observe a correlation between number of micrometastases in the bone marrow and T cell responsiveness...
  46. ncbi Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer
    John W Park
    University of California, San Francisco, San Francisco, CA 94115 1710, USA
    J Clin Oncol 25:3680-7. 2007
    ..We conducted a phase I study to evaluate the safety and immunologic activity of lapuleucel-T in patients with HER-2-overexpressing metastatic breast cancer...
  47. ncbi Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging
    Ka Loh Li
    Department of Radiology, University of California, San Francisco, 1 Irving St, San Francisco, CA 94143 1290, USA
    Radiology 248:79-87. 2008
    ..To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with breast cancer who underwent preoperative magnetic resonance (MR) imaging...
  48. ncbi Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease
    Robert D Foster
    Division of Plastic and Reconstructive Surgery, Department of Surgery, University of California, San Francisco, CA 94143 0932, USA
    Arch Surg 140:196-8; discussion 199-200. 2005
    ..Immediate transverse rectus abdominis myocutaneous breast reconstruction combined with postoperative radiation therapy after mastectomy is safe and effective...
  49. ncbi Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse
    Michael J Campbell
    Department of Surgery, University of California San Francisco Mount Zion Medical Center, 1600 Divisadero, San Francisco, CA 94115, USA
    In Vitro Cell Dev Biol Anim 38:326-33. 2002
    ..In addition, the tumor-derived fibroblast line may be useful for studying tumor-stromal cell interactions...
  50. ncbi Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients
    Elisabeth R Garwood
    Department of Surgery, Carol Franc Buck Breast Care Center, University of California at San Francisco, San Francisco, CA 94115, USA
    Ann Surg 249:26-32. 2009
    ..We sought to define the impact of surgical and reconstructive variables on complication rates and assess how changes in technique affect outcomes...
  51. ncbi Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis
    Elissa M Ozanne
    Institute for Technology Assessment at Massachusetts General Hospital, Department of Radiology, Harvard Medical School, 101 Merrimac Street, 10th Floor, Boston, MA 02114 4724, USA
    Cancer Epidemiol Biomarkers Prev 13:2043-52. 2004
    ..Assess the effectiveness and cost-effectiveness of using biomarkers and risk assessment tools to stratify women for breast cancer preventive interventions...
  52. ncbi Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Blvd, Unit 1202, Houston, TX 77030, USA
    J Clin Oncol 26:791-7. 2008
    ..To review the state of the science with respect to diagnostic imaging and locoregional therapy for patients with breast cancer receiving preoperative chemotherapy...
  53. ncbi Genetic/familial high-risk assessment: breast and ovarian
    Mary B Daly
    Fox Chase Cancer Center, Philadelphia, PA, USA
    J Natl Compr Canc Netw 4:156-76. 2006
  54. ncbi Breast cancer risk assessment and prevention: a framework for shared decision-making consultations
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Breast J 12:103-13. 2006
    ..The framework is intended to encourage a shared decision-making approach to prevention consultations, a method for researchers to increase accrual to trials, and to more quickly incorporate new findings into the routine of practice...
  55. ncbi Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template
    Karen R Sepucha
    Harvard Medical School, Boston, MA, USA
    Oncol Nurs Forum 30:99-106. 2003
    ..To describe two templates that can be used to improve the quality of breast cancer treatment decisions...
  56. ncbi Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
    Julia D Wulfkuhle
    Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110, USA
    J Proteome Res 7:1508-17. 2008
    ..Analysis of biopsy material from clinical trials for targeted therapeutics demonstrates the feasibility and utility of comprehensive signal pathway activation profiling for molecular analysis...
  57. ncbi Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians
    Karen R Sepucha
    Harvard Medical School, Boston, MA, USA
    J Clin Oncol 20:2695-700. 2002
    ....
  58. ncbi A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes
    Anjali S Kumar
    J Clin Oncol 24:2127; author reply 2127-8. 2006
  59. ncbi Clinical trials are required to prove the chemopreventive worth of statins
    Anjali S Kumar
    Arch Intern Med 166:1143; author reply 1144. 2006

Research Grants2

  1. Integrated Biomarkers to Characterize Breast Cancer Risk
    Laura Esserman; Fiscal Year: 2007
    ....